COVID-19：Fujifilm和礼来公司签约：抗体药物的原料药生产
-旨在传播到低收入和中等收入国家-
富士Diosynth Biotech（FDB）
我们已受委托为礼来公司生产用于新型冠状病毒感染的API药物。
富士Diosynth Biotech（FDB）：
从2021年4月起，我们将在丹麦的基地开始生产。
礼来公司针对COVID-19的抗体药物将有助于向低收入和中等收入国家的传播。
富士胶卷[日本]
https://www.fujifilm.com/jp/ja/news/list/5537
FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody
for Low- and Middle-Income Countries
ILLERØD, Denmark,
October 8, 2020 —
FUJIFILM Diosynth Biotechnologies,
a world leading Contract Development and Manufacturing Organization (CDMO)
for biologics, viral vaccines and viral vectors,
today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP* facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.
The commercial manufacturing falls under the agreement between Lilly and the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator,
to supply potential Lilly therapeutic antibodies for the prevention and treatment of COVID-19.
The Therapeutics Accelerator is an initiative launched by
- the Gates Foundation,
- Wellcome,
- Mastercard
to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments
Fujifilm Global
https://www.fujifilm.com/news/n201009_02.html